Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04884477 · ClinicalTrials.gov registry record
COVID-19 Infection in Patients Receiving Anti-CD20 Therapy
A clinical trial of COVID-19 and Convalescent Plasma, sponsored by Mayo Clinic.
- Completed
- Registry status
- 342
- Enrollment target
- 1
- Study location
NCT04884477: Completed study of COVID-19 and Convalescent Plasma, sponsored by Mayo Clinic.
NCT04884477 is a study of COVID-19 and Convalescent Plasma that has completed, run by Mayo Clinic. The registered enrollment target is 342 participants, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04884477, a study of COVID-19 and Convalescent Plasma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 342 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.
Primary Outcome
In this observational study examining the use of convalescent plasma (CP) for treatment of CD20-depleted patients with COVID-19, we will describe the clinical course of these patients and conduct a comparative treatment analysis. "Time zero" will be considered the date the patient first tested positive for COVID-19, and the time-dependent nature of CP transfusion will be explicitly used in the analysis. The primary outcome of interest is the WHO ordinal outcome score measured repeatedly over 90-
Conditions Studied
Interventions
- BIOLOGICAL Convalescent Plasma
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 342 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2023-01-15 |
What the finished NCT04884477 record still lists
NCT04884477 is an observational study that tracks outcomes without assigning an intervention. The registered 342 participants enrollment target is mid-sized for trials with a published cap, below the 38,464-participant average among 298 other COVID-19 trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04884477 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT04884477 about?
NCT04884477 is a clinical study titled "COVID-19 Infection in Patients Receiving Anti-CD20 Therapy". This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.
What is the current status of trial NCT04884477?
This trial is currently completed. The enrollment target is 342 participants. The study started on 2021-06-01. Estimated completion is 2023-01-15.
What conditions does trial NCT04884477 study?
This clinical trial studies the following conditions: COVID-19, Convalescent Plasma, Immunosuppressed Host, Anti-CD20 Therapy.
What interventions are being tested in trial NCT04884477?
The interventions under investigation include: Convalescent Plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04884477?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04884477 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04884477's enrollment target sits among peer trials
342 135th of 298 higher than 164 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
- NCT05714085 · 342 participants · Phase 2
Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)
- NCT06188702 · 342 participants · Phase 1
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
- NCT06544941 · 342 participants · NA
Improving Maternal Sleep and Mental Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI